Pharmaxi LLC is a CRO founded in 2013 by two MDs whose dream was to build the best CRO in the world. The main idea was to make complex clinical trials easy for the client.
We are focused on clinical trials of medical products, medical devices, and dietary supplements. Pharmaxi provides services in Poland, Ukraine, and other Eastern European countries. Currently, we have 34 employees, divided into several departments: Clinical Operations, Data Management, and Biometrics.
We work with both large (Sanofi, AbbVie, Takeda) and small (Sankom, Peptigroup, Flyser) pharmaceutical and biotech companies from 21 European and North American countries.
Pharmaxi LLC is a client-oriented, flexible, innovative and cost-effective Contract Research Organization.
Pharmaxi LLC focuses on the planning and management of projects that generate clinical evidence. We conduct clinical trials, post-marketing studies, and registries to collect clinical and performance data for medicines, medical devices, and IVD products. A dedicated team, in collaboration with our German consulting partners, also develops technical documentation reviews and clinical evaluation plans and reports.
The company is skilled at performing all trial activities, from study design negotiation to the creation of the final study report. You can rely on us even if you have specific tasks not covered by our in-house facilities, such as drug depot, logistics, insurance, and delivery services. These activities are delegated to trusted and fully-vetted subcontractors. For more information about our services, please visit this page.
Over the years, we have completed projects in the fields of cardiology, endocrinology, gastroenterology, pulmonology, pediatrics, nephrology, gynecology, oncology, neurology, rheumatology, and orphan diseases. We are also equipped to conduct clinical trials in other therapeutic areas.
| Featured projects | Number of items | Number of sites |
|---|---|---|
| Chronic pancreatitis (randomized, double-blind, double-dummy) | 210 | 7 |
| Comparison of a new formulation of XXXX to XXXX in patients with dysfunctional uterine bleeding requiring endometrial ablation (randomized, single-blind). | 90 | 6 |
| Parallel group single-blind study to compare the pharmacokinetic profiles and pharmacodynamic response of a new depot formulation of XXXX to XXXXXX in ambulatory patients with advanced carcinoma of the prostate | 160 | 8 |
| A Multi-center, Randomized, Double-blind, Comparative Study to Evaluate the Safety and Efficacy of ZTI-01 Versus XXXX in the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis, in Hospitalized Adults | 110 | 6 |
| Phase II, Prospective, Multi-center, Randomized, Controlled, Two arms, double Blind Study to assess Efficacy and Safety of XXX Administered Concomitantly with the Standard of Care (SOC), compared to SOC treated control arm, in the prevention of post abdominal surgery incisional infection. | 120 | 9 |
| A multi-center, randomized, double-blind, placebo-controlled, parallel-group trial to assess the antiviral efficacy and safety of XXXX in subjects with moderate Covid-19 in Standard of Care Setting | 540 | 17 |
| A phase III, multi-center, international, randomized, assessor-blind, parallel-arm study to evaluate the efficacy, safety, and tolerability of XXX in comparison to XXXX in relapsing-remitting multiple sclerosis (RRMS) patients | 125 | 6 |
